Nath Bio-Genes (I) Ltd
NATHBIOGENNath Bio-Genes (I) Ltd
NATHBIOGEN
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 8.60 | 0.58 | 1.08% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.87 | 9.99 | 1.48% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Nath Bio-Genes (India) is engaged in hybrid seed business and production, processing and marketing of hybrid and genetically modified (GM) seeds
Peers
Compare with peersGodrej Agrovet Ltd
Gujarat Ambuja Exports Ltd
Sanstar Ltd
Cian Agro Industries & Infrastructure Ltd
Fratelli Vineyards Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2022 | FY 2023 | FY 2024 | TTM | ||||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 280.21 | 301.91 | 336.70 | 354.95 | ||||
Raw Materials | 3.56 | 5.31 | 12.26 | 299.92 | ||||
| Power & Fuel Cost | 1.07 | 1.39 | 1.13 | |||||
| Employee Cost | 24.78 | 23.32 | 27.58 | |||||
| Selling & Administrative Expenses | 89.99 | 112.25 | 139.47 | |||||
| Operating & Other expenses | 210.53 | 110.26 | 102.23 | |||||
EBITDA | -49.72 | 49.38 | 54.03 | 55.03 | ||||
| Depreciation/Amortization | 3.08 | 3.01 | 3.26 | 3.40 | ||||
| PBIT | -52.80 | 46.37 | 50.77 | 51.63 | ||||
| Interest & Other Items | 10.64 | 10.21 | 9.20 | 9.13 | ||||
| PBT | -63.44 | 36.16 | 41.57 | 42.50 | ||||
| Taxes & Other Items | 3.95 | 1.13 | 1.95 | 1.60 | ||||
| Net Income | -67.39 | 35.03 | 39.62 | 40.90 | ||||
| EPS | -35.46 | 18.43 | 20.85 | 21.52 | ||||
| DPS | 2.00 | 2.00 | 2.00 | 2.00 | ||||
| Payout ratio | — | 0.11 | 0.10 | 0.09 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Consumer StaplesAgro Products
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nath Bio-Genes (I) Ltd | 8.88 | 0.58 | 1.08% |
| Godrej Agrovet Ltd | 38.80 | 4.78 | 1.38% |
| Gujarat Ambuja Exports Ltd | 16.58 | 2.07 | 0.28% |
| Sanstar Ltd | 32.51 | 8.55 | — |
Price Comparison
Compare NATHBIOGEN with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.68%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Nath Bio-Genes (I) Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Aditya Birla Sun Life Pure Value Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 4.4874% | Percentage of the fund’s portfolio invested in the stock 0.25% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 37/87 (0) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 9, 2024
Dividend/Share
₹2.00
Ex DateEx Date
Aug 9, 2024
Cash Dividend
Ex DateEx DateJul 4, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Jul 4, 2023
Cash Dividend
Ex DateEx DateJun 23, 2022
Dividend/Share
₹2.00
Ex DateEx Date
Jun 23, 2022
Cash Dividend
Ex DateEx DateAug 18, 2021
Dividend/Share
₹2.00
Ex DateEx Date
Aug 18, 2021
Net profit of Nath Bio-Genes (India) declined 26.49% to Rs 1.11 crore in the quarter ended September 2024 as against Rs 1.51 crore during the previous quarter ended September 2023. Sales rose 42.62% to Rs 32.19 crore in the quarter ended September 2024 as against Rs 22.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales32.1922.57 43 OPM %14.9422.06 - PBDT1.912.61 -27 PBT1.091.85 -41 NP1.111.51 -26 Powered by Capital Market - Live
Net profit of Nath Bio-Genes (India) rose 79.50% to Rs 2.89 crore in the quarter ended September 2024 as against Rs 1.61 crore during the previous quarter ended September 2023. Sales rose 42.62% to Rs 32.19 crore in the quarter ended September 2024 as against Rs 22.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales32.1922.57 43 OPM %20.3822.60 - PBDT3.692.72 36 PBT2.861.96 46 NP2.891.61 80 Powered by Capital Market - Live
Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
Net profit of Nath Bio-Genes (India) declined 0.24% to Rs 33.35 crore in the quarter ended June 2024 as against Rs 33.43 crore during the previous quarter ended June 2023. Sales rose 3.66% to Rs 243.88 crore in the quarter ended June 2024 as against Rs 235.28 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales243.88235.28 4 OPM %14.9815.74 - PBDT34.4334.38 0 PBT33.6033.62 0 NP33.3533.43 0 Powered by Capital Market - Live
Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 7 August 2024.Powered by Capital Market - Live
Dividend paying stocks 2022: 5 stocks to turn ex-dividend tomorrow
Nath Bio-Genes (India) standalone net profit declines 59.14% in the September 2021 quarter
Minda Corporation Ltd leads gainers in ‘A’ group
Top stocks in focus: Aarey Drugs & Pharmaceuticals, Fortis Malar Hospitals, Nath Bio-Genes, Pricol, Gujarat Alkalies and Chemicals
Nath Bio-Genes (India) standalone net profit rises 8.85% in the June 2021 quarter
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant